Jpmorgan Chase & CO Hille Vax, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Hille Vax, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 33,402 shares of HLVX stock, worth $58,787. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,402
Previous 47,072
29.04%
Holding current value
$58,787
Previous $782,000
38.36%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HLVX
# of Institutions
93Shares Held
40.5MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$18.7 Million9.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4MShares$7.05 Million1.22% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.48MShares$6.13 Million0.03% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.68 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.99MShares$3.5 Million0.01% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $58.8M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.